"Is that the company or the concept?"
The CFO asked that in March 2024, pointing at page 14 of a capital request I'd spent six weeks building. The program description read: "intuitive surgical operations expansion."
And I couldn't answer.
(Should mention: we were mid-prep for a Joint Commission survey that spring, and the CFO was reading every capital dollar twice. That context matters, because it's why one ambiguous phrase on page 14 snowballed into a six-month project.)
Quick background: I handle capital equipment procurement for a 400-bed community hospital. Eight years in. I've made my share of mistakes, but this one was the most instructive, because it exposed a category error that was quietly costing us time, money, and credibility.
My assignment was to recommend a diagnostic instrument pathway for the pulmonary nodule program. Instead, I got tangled in the phrase "intuitive surgical" - and the confusion between the publicly traded company Intuitive Surgical and the descriptor intuitive surgical technique nearly sent a major purchase in the wrong direction.
The surface problem: a name that means two things
Here's what nobody warns you about: Intuitive Surgical, the company, has a name that doubles as a description. "Intuitive surgical" just sounds like surgery that flows naturally. I've heard surgeons at conferences use it loosely. I've used it myself.
The search phrase "intuitive surgical or intuitive surgical" shows up in our hospital library referral logs - I know, because I looked it up after the CFO question. It's not just me. And when I searched the keyword intuitive-surgical (hyphenated, the way our procurement portal auto-formats brand tags), I got the same mixture: papers about the da Vinci system next to papers using "intuitive" to describe a technique.
Most buyers in my position focus on the robot. The da Vinci system is famous, it's proven, and it's the flagship. But most buyers completely miss the rest of the picture: the company's operations also include a robotic-assisted diagnostic platform (Ion), a next-generation multiport system (da Vinci 5), instruments, endoscopes, and training.
In other words, "intuitive surgical operations" wasn't a vague phrase on my capital request. It was literally the scope of what the company does. I had labeled a major budget item with a term I didn't understand well enough to defend.
But the terminology problem was just the visible part. The deeper problem took three more months to surface.
Where the confusion actually comes from
Cause one: the brand became a synonym for the method
This was true fifteen years ago, when Intuitive Surgical was effectively da Vinci and da Vinci was Intuitive Surgical. You could say "we're going Intuitive" in a capital committee meeting and everyone knew exactly what you meant.
Today, that shorthand is broken. The company added Ion, a robotic-assisted bronchoscopy platform built for peripheral lung biopsies - a diagnostic instrument in everything but the marketing category - and then expanded the instrument line, built the SP platform, and launched da Vinci 5.
The "Intuitive Surgical equals surgical robots" thinking comes from an era when one product defined the company. That changed. But my mental filing system hadn't. And because I filed the company under "surgical robots," I never once considered its products when the pulmonary committee asked for diagnostic instrument recommendations.
Cause two: the diagnostic instrument that didn't fit my category
The pulmonary team wanted a navigation bronchoscopy platform - a way to biopsy the small peripheral lung nodules that standard bronchoscopes can't reliably reach. I built a vendor list, complete with a spec sheet that had a column for "robotic vs. manual."
No Ion. Because Ion is robotic, and I'd categorized "robotic" under surgery, not diagnostics.
My pulmonologist colleague caught it in April 2024. "Why aren't we looking at Intuitive's Ion?"
Silence.
To be fair, the company's reps had mentioned Ion. They'd mentioned it in the first meeting, actually. But I filtered it out of my notes because it didn't match my schema. And the people on our surgical capital committee weren't on the pulmonary committee. Meeting minutes didn't cross. So the diagnostic instrument most likely to meet our clinical need sat in a mislabeled corner of my head for three months.
Cause three: gel electrophoresis and the invisibility problem
The OR nursing director asked a question during the next vendor demo that stopped the room.
"What's your protein residue test?"
I had no idea what she was talking about.
She explained, with the patience of someone who knows they're right: reprocessed surgical instruments must be free of biological residue. You can't see protein on a device with the naked eye. So how do you verify that "cleaned and sterilized" actually means clean?
The answer involves gel electrophoresis. Specifically, SDS-PAGE: you extract any protein from a reprocessed instrument, run it through a gel, stain it, and look for bands. Bands mean residue. It's the same basic biology-lab technique from college, and I'd never connected it to instrument evaluation.
She was checking whether the vendor's reprocessing claims held up against our own sterilization logs. That's a verification step most of us skip. We trust the label and the FDA clearance, then never test the instruments in our own facility. The vendor provided their gel electrophoresis data. It checked out - good for them. But the fact that they had it ready, and our side had never thought to ask for it, said a lot about how shallow our evaluation had been.
Per AAMI ST98, the cleaning-validation standard for reusable medical devices, residual protein testing after reprocessing is part of the recommended verification approach (Source: AAMI, aami.org). I'm not going to pretend I knew that before March 2024. I didn't. The nursing director did.
Cause four: how does a CGM work? (the monitoring gap)
Somewhere around month four, I was reading about continuous glucose monitoring at midnight. A patient on our lung-surgery waitlist had poorly controlled type 2 diabetes, and I realized I couldn't explain the technology I was implicitly leaving out of our surgical pathway.
How does a CGM work? Short version: a small sensor sits under the skin, measures glucose in the interstitial fluid, and a transmitter converts that signal into a glucose reading every few minutes. No fingersticks between calibrations. It's a diagnostic instrument in the monitoring sense, and it matters in surgery because glucose variability is associated with surgical-site infection and slower recovery. The American Diabetes Association's 2025 Standards of Care discuss the expanding role of CGM in inpatient glucose monitoring (Source: ADA, diabetesjournals.org).
Now, which surgical robot vendor brought up CGM? None. It's not their product. But the fact that our capital committee never asked about glucose monitoring during a six-month surgical technology evaluation - with an increasingly older, more diabetic surgical population - is exactly the silo problem this story is about.
What the confusion actually cost
Let me put a number on it.
Six weeks of capital-request work on the wrong framing: roughly $12,000 in my salaried time, conservative estimate. The abandoned diagnostic instrument competitive evaluation (started May 2024, cancelled September 2024): around $18,000 when you count vendor demo logistics, physician time, and travel. Two vendor evaluations that produced no purchase: about $15,000.
Total: $45,000. Maybe $45,000 give or take - I'd have to check the final accounting. Either way: no equipment, no improved workflow, and a binder full of documents that said, in effect, we asked the wrong question.
The quieter cost was credibility. I'd been the guy who "knew the market." After the gel electrophoresis question, I had to rebuild trust with the OR nursing team. She was right to be annoyed - I should have asked for her input before the vendor demo, not during it.
And then there was the timeline cost for the pulmonary nodule program: six months without a definitive navigation-bronchoscopy option on site. I can't claim a specific patient was harmed; I won't overreach. But our first-year procedure volume target took a real hit. When you delay a diagnostic capability, the people who lose are the ones waiting for answers.
The checklist I wish I'd had
After the September 2024 cancellation, I wrote down the process that now governs our capital equipment reviews. It's short, and it's designed to catch exactly what I missed.
- Name the clinical workflow first. Not the product category. "Peripheral lung nodule biopsy," not "robotic bronchoscopy system."
- Ask what category you're anchored to. If you keep calling Intuitive Surgical "the surgical robot company," you'll miss Ion. Write down the assumption. Look for the evidence that breaks it.
- Invite the people outside the capital request chain. Sterile processing, diabetes education, the OR nursing director, the pulmonologist. They know things the vendor reps don't.
- Ask every vendor what they don't do. The Intuitive Surgical rep said their team doesn't make CGM devices, explained how their system could integrate alongside a monitoring vendor's platform, and told us who actually does that well. That honesty earned more trust than any spec sheet. I'd rather work with a specialist who knows their limits than a generalist who overpromises.
- Verify one claim per major purchase. Gel electrophoresis for protein residue. Sterility logs for reprocessing. Whatever applies - just run the test.
We've caught 47 potential issues using this checklist since September 2024. Maybe 42, I'd have to check the log. The exact number matters less than the pattern: nearly all of them were the same category error - evaluating a product before defining the workflow.
The answer to the original question
If you're here searching "intuitive surgical or intuitive surgical," you're asking the same question I was: company or concept?
The honest answer is both. Intuitive Surgical is a company whose operations span therapeutic and diagnostic robotics. "Intuitive surgical" still describes a technique that feels natural to the surgeon. But the useful reframe is to stop sorting vendors into categories and start with the clinical problem you're solving.
The technology isn't the star. The workflow is. And if you ask a good vendor what they're bad at, they'll tell you - which is how you know they're good.